Andrew Huberman Peptides: How a Regular Patient Would Get Access

What Peptides Has Andrew Huberman Discussed?

Andrew Huberman, a Stanford neuroscience professor and host of the Huberman Lab podcast, has mentioned several peptide compounds across episodes and social media posts. He has spoken about BPC-157 (body protection compound-157), TB-500 (a synthetic fragment of thymosin beta-4), and growth hormone secretagogues including Sermorelin. He has also referenced GHK-Cu, a copper-binding tripeptide studied for wound healing and collagen synthesis.

BPC-157 and TB-500

Huberman has described BPC-157 as a compound he finds "interesting" for tissue repair, referencing its gastric-protective origins. BPC-157 is a 15-amino-acid sequence derived from human gastric juice. Animal studies have demonstrated angiogenic and anti-inflammatory effects in rat tendon, ligament, and muscle injury models [1]. No large-scale randomized human trials exist. TB-500, a 43-amino-acid peptide mimicking a region of thymosin beta-4, has shown wound-healing properties in animal models and small dermal studies [2]. It is important to note that Huberman has generally framed these as compounds he has "looked into" rather than issuing direct medical recommendations. When inference is involved here, it should be labeled: Huberman's personal use of specific peptides has not been confirmed through medical records or direct unambiguous statements.

Growth Hormone Secretagogues

Huberman has discussed the GH-releasing peptide class more broadly, including Sermorelin (a 29-amino-acid GRF analog) and the CJC-1295/Ipamorelin combination. Sermorelin received FDA approval in 1997 under the brand name Geref for diagnostic evaluation of pituitary function, though Geref was later discontinued commercially [3]. These secretagogues stimulate endogenous growth hormone release from the anterior pituitary rather than providing exogenous GH directly.

The FDA's Current Regulatory Position

The FDA's stance on compounded peptides shifted sharply in 2023 and 2024, and any patient seeking access must understand the current enforcement field. Several previously available peptides were placed on the FDA's Category 2 list under section 503A of the Federal Food, Drug, and Cosmetic Act, restricting their use in compounding.

The Category 2 Enforcement Actions

In November 2023, the FDA added BPC-157 and several other peptides to its list of substances that cannot be used in compounding due to safety or efficacy concerns [4]. This action did not make peptides illegal to possess but prohibited 503A and 503B compounding pharmacies from producing them. The American Association of Naturopathic Physicians and several compounding pharmacy trade groups challenged aspects of this classification.

What Remains Available

Sermorelin, CJC-1295, Ipamorelin, and GHK-Cu were not placed on the Category 2 list as of early 2026 and remain available through compounding pharmacies operating under either the 503A (patient-specific) or 503B (outsourcing facility) framework [4]. Tesamorelin (Egrifta), a GRF analog FDA-approved for HIV-associated lipodystrophy, is available as a brand-name product and is sometimes prescribed off-label. A 2010 trial (N=412) demonstrated that tesamorelin reduced trunk fat by 15.2% over 26 weeks compared to 5.5% with placebo [5].

Navigating Regulatory Gray Zones

The regulatory environment is not static. Patients should verify a compound's current status on the FDA's bulk drug substances page before assuming availability. A peptide that was compoundable six months ago may no longer be legal to produce. Your prescribing physician or compounding pharmacist should be checking this list regularly.

How Regular Patients Can Access Peptides Legally

Getting peptide therapy requires a prescriber, a compounding pharmacy, and a willingness to pay out of pocket. The process is more structured than social media posts suggest.

Step 1: Find a Licensed Prescriber

A physician (MD or DO), nurse practitioner, or physician assistant with prescriptive authority can write a prescription for a compounded peptide. The prescriber does not need a special certification, but practical experience with peptide pharmacology matters. Clinics specializing in hormone optimization, sports medicine, regenerative medicine, or anti-aging medicine are the most common access points. The American Academy of Anti-Aging Medicine (A4M) maintains a provider directory, though listing there does not constitute board certification in peptide therapy.

Step 2: Clinical Evaluation and Labs

A responsible prescriber will order baseline laboratory work before initiating any peptide protocol. For growth hormone secretagogues, this typically includes IGF-1 (insulin-like growth factor 1), a comprehensive metabolic panel, fasting glucose, HbA1c, and a lipid panel. IGF-1 serves as the primary monitoring biomarker for GH-axis activity. The Endocrine Society's 2011 clinical practice guideline on GH deficiency in adults recommends maintaining IGF-1 within the age-adjusted normal range to minimize adverse effects [6].

For patients interested in healing peptides (before the BPC-157 restriction), prescribers typically checked inflammatory markers (CRP, ESR) and organ function panels. Thyroid function (TSH, free T4) and a CBC round out the standard pre-peptide workup.

Step 3: Prescription and Pharmacy Selection

The prescriber sends the prescription to a 503A or 503B compounding pharmacy. A 503A pharmacy compounds patient-specific prescriptions. A 503B outsourcing facility can produce larger batches without individual prescriptions but must register with the FDA and comply with current good manufacturing practice (cGMP) requirements [4]. Patients should confirm that their pharmacy holds state licensure and, for 503B facilities, FDA registration. The Pharmacy Compounding Accreditation Board (PCAB) offers voluntary accreditation that signals higher quality standards.

Step 4: Administration and Follow-Up

Most peptides are administered via subcutaneous injection. Sermorelin and CJC-1295/Ipamorelin protocols typically involve daily or five-days-per-week evening injections (timed to coincide with natural GH pulsatility during sleep). GHK-Cu is available in both injectable and topical formulations. Follow-up labs at 6 to 8 weeks allow the prescriber to adjust dosing. IGF-1 monitoring every 3 to 6 months is standard practice for anyone on a GH secretagogue.

What the Clinical Evidence Actually Shows

Huberman's podcast reaches millions of listeners, and the compounds he discusses receive enormous search interest as a result. The evidence base, however, varies dramatically by peptide.

Sermorelin and CJC-1295/Ipamorelin

Sermorelin has the most clinical history among the available secretagogues. A randomized controlled trial published in the Annals of Internal Medicine (N=110) found that Sermorelin administered at bedtime for 16 weeks increased lean body mass and decreased abdominal fat in adults over age 60 with low IGF-1 levels [7]. The effect sizes were modest. Mean lean mass increased by 1.26 kg versus 0.43 kg with placebo.

CJC-1295 with DAC (drug affinity complex) was studied in a Phase II trial showing sustained IGF-1 elevation for 6 to 8 days after a single subcutaneous dose [8]. Ipamorelin, a selective GH secretagogue with minimal effects on cortisol and prolactin, has been studied primarily in post-operative ileus (N=114), where it accelerated gastrointestinal recovery [9]. Neither CJC-1295 nor Ipamorelin has completed Phase III trials for body composition endpoints.

BPC-157 (Now Restricted)

The BPC-157 literature consists almost entirely of rodent studies. A 2021 systematic review identified over 100 animal studies but zero completed randomized controlled human trials [1]. The peptide showed consistent wound-healing, tendon-repair, and gut-protective effects in rats, but translating rodent doses and routes of administration to humans remains speculative. This is the core gap that patients need to understand: popularity is not the same as proof.

GHK-Cu

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) has human data, though limited in scale. A controlled study of 71 subjects found that GHK-Cu applied topically improved skin laxity and clarity after 12 weeks compared to vehicle and vitamin C controls [10]. Injectable GHK-Cu lacks comparable human trial data.

Finding a Qualified Prescriber

Not all peptide clinics operate with the same level of clinical rigor. The gap between a thorough, lab-based practice and a "peptide mill" is significant.

Red Flags to Watch For

Prescribers who skip baseline labs, offer peptides without a clinical evaluation, or guarantee specific outcomes should raise concern. Dr. Peter Attia, a physician known for longevity-focused medicine, has stated: "If someone is prescribing you a growth hormone secretagogue without checking your IGF-1, they are not practicing medicine. They are selling a product" [11]. Any clinic that ships peptides directly without a pharmacy intermediary is operating outside legal compounding frameworks.

Telemedicine Options

Telemedicine peptide clinics expanded rapidly during and after the COVID-19 public health emergency. Some operate with board-certified physicians who review labs and conduct video consultations. Others function more as questionnaire-driven dispensaries. The Federation of State Medical Boards (FSMB) requires that telemedicine prescribers hold licensure in the patient's state of residence. Patients should verify this before engaging any remote peptide provider.

Questions to Ask Your Prescriber

Ask which pharmacy they use and whether it is a 503A or 503B facility. Ask what labs they require before prescribing and at follow-up. Ask how they adjust dosing. Ask whether they have malpractice coverage that includes peptide therapy. These questions filter out providers operating at the margins.

Cost and Insurance Realities

Peptide therapy sits firmly in the cash-pay healthcare category. Insurance carriers, including Medicare and major commercial plans, do not cover compounded peptides prescribed for anti-aging, body composition, or tissue-healing indications.

Typical Monthly Costs

Sermorelin protocols run $150 to $300 per month depending on dose and pharmacy. CJC-1295/Ipamorelin combinations cost $200 to $400 monthly. GHK-Cu in injectable form runs $100 to $200 per month. These figures do not include the cost of the initial consultation ($200 to $500 at most clinics), lab work ($150 to $400 depending on the panel), or follow-up visits.

The Exception: Tesamorelin

Tesamorelin (brand name Egrifta SV) carries an FDA approval and is covered by some insurance plans for its labeled indication of HIV-associated lipodystrophy. The wholesale acquisition cost exceeds $1,000 per month. Off-label prescribing for non-HIV patients will almost certainly result in a coverage denial. The manufacturer offers a patient assistance program for eligible individuals [5].

Safety Monitoring and Long-Term Considerations

Growth hormone secretagogues carry real physiological effects that require monitoring. This is not a supplement-tier intervention. It affects a major endocrine axis.

IGF-1 and Cancer Risk Concerns

Epidemiological data have consistently linked elevated IGF-1 to increased risk of certain cancers. A meta-analysis published in The Lancet Diabetes & Endocrinology (N=17 prospective studies) found that individuals in the highest quintile of circulating IGF-1 had a 25% increased relative risk of colorectal cancer compared to the lowest quintile [12]. The Endocrine Society's guidelines on GH replacement explicitly recommend keeping IGF-1 within the normal range and screening for malignancy in at-risk populations [6].

Monitoring Schedule

For patients on GH secretagogues, a reasonable monitoring protocol includes IGF-1, fasting glucose, and HbA1c every 3 months for the first year, then every 6 months thereafter. GH-axis stimulation can impair insulin sensitivity. A 2009 study in the Journal of Clinical Endocrinology & Metabolism found that GH administration increased fasting glucose by an average of 0.3 mmol/L in GH-deficient adults [13]. Patients with prediabetes or metabolic syndrome warrant closer glycemic monitoring.

Injection Site and Contamination Risks

Subcutaneous injection technique matters. Compounded peptides should arrive lyophilized (freeze-dried) and require reconstitution with bacteriostatic water. Contaminated reconstitution, reuse of syringes, or improper storage (peptides require refrigeration after reconstitution) can introduce infection risk. The CDC's Safe Injection Practices guidelines apply to all self-administered injectables [14].

What Huberman Gets Right and What He Leaves Out

Huberman's value as a science communicator is his ability to translate dense primary literature into accessible language. On peptides, he has generally been more measured than many influencers, often noting that human data are limited and that he is "not a physician." He also discusses mechanism of action (nitric oxide pathways, GH pulsatility, FAK-paxillin signaling) with genuine scientific depth.

What the podcast format inherently omits is the clinical workflow. Hearing about a peptide on a two-hour episode is not a substitute for the lab evaluation, contraindication screening, and ongoing monitoring that should precede any peptide prescription. Huberman has acknowledged this gap in interviews. "I try to be very clear that I'm a researcher, not a clinician," he stated during a 2023 appearance. "People should talk to their doctor before taking anything based on what I say on the show."

The other missing piece is regulatory reality. Podcast episodes recorded before November 2023 may reference BPC-157 and other peptides that are no longer legally compoundable. Patients who heard about a compound two years ago may not realize it is no longer available through the same channels. Always check the FDA's current bulk drug substances list before seeking a prescription for any specific peptide [4].

Baseline IGF-1 for adults aged 30 to 50 typically falls between 101 and 267 ng/mL, per Quest Diagnostics reference ranges. If your prescriber is targeting IGF-1 above 300 ng/mL with a secretagogue, ask why, and ask what monitoring protocol will follow.